Caplin Point Laboratories LimitedNSE: CAPLIPOINT

Press Release Sep 20 2023

· Issued by Caplin Point Laboratories Limited

Filed with NSE ·

Caplin Point Laboratories Limited has informed the Exchange regarding a press release dated September 20, 2023, titled "Press Release regarding grant of final approval by the United States Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) Norepinephrine Bitartrate Injection USP, to our Subsidiary Caplin Steriles Limited. ".

View Attachment

6ix hasn’t read this filing yet.

Caplin Point Laboratories Limited on 6ix

Earlier from Caplin Point Laboratories

Later from Caplin Point Laboratories

All Caplin Point Laboratories news releases